794 related articles for article (PubMed ID: 27135594)
1. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
[TBL] [Abstract][Full Text] [Related]
2. Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports.
Forci B; Mariottini A; Mechi C; Massacesi L; Repice A
Mult Scler Relat Disord; 2017 Jul; 15():24-26. PubMed ID: 28641768
[TBL] [Abstract][Full Text] [Related]
3. Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.
Nygaard GO; Torgauten H; Skattebøl L; Høgestøl EA; Sowa P; Myhr KM; Torkildsen Ø; Celius EG
Mult Scler Relat Disord; 2022 Jun; 62():103812. PubMed ID: 35462167
[TBL] [Abstract][Full Text] [Related]
4. Frequency and risk factors of rebound after fingolimod discontinuation - A retrospective study.
Maunula A; Atula S; Laakso SM; Tienari PJ
Mult Scler Relat Disord; 2024 Jan; 81():105134. PubMed ID: 37980790
[TBL] [Abstract][Full Text] [Related]
5. Clinical activity after fingolimod cessation: disease reactivation or rebound?
Frau J; Sormani MP; Signori A; Realmuto S; Baroncini D; Annovazzi P; Signoriello E; Maniscalco GT; La Gioia S; Cordioli C; Frigeni B; Rasia S; Fenu G; Grasso R; Sartori A; Lanzillo R; Stromillo ML; Rossi S; Forci B; Cocco E;
Eur J Neurol; 2018 Oct; 25(10):1270-1275. PubMed ID: 29851435
[TBL] [Abstract][Full Text] [Related]
6. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
7. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
Sánchez P; Meca-Lallana V; Vivancos J
Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
[TBL] [Abstract][Full Text] [Related]
8. Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors.
Sepúlveda M; Montejo C; Llufriu S; Sola-Valls N; Reyes D; Martinez-Lapiscina EH; Zubizarreta I; Pulido-Valdeolivas I; Martinez-Hernandez E; Ariño H; Baños N; Saiz A; Blanco Y
Mult Scler Relat Disord; 2020 Feb; 38():101483. PubMed ID: 31734621
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with fingolimod rebound: A single center real-life experience.
Goncuoglu C; Tuncer A; Bayraktar-Ekincioglu A; Ayvacioglu Cagan C; Acar-Ozen P; Cakan M; Karabulut E; Karabudak R
Mult Scler Relat Disord; 2021 Nov; 56():103278. PubMed ID: 34655957
[TBL] [Abstract][Full Text] [Related]
10. Rebound activity after fingolimod cessation: A case - control study.
Barboza A; Gaitán MI; Alonso R; Ysrraelit MC; Luetic G; Liwacki S; Patrucco L; Halfon MJ; Burgos M; Mainella C; Pierdabuena R; Recchia L; Steinberg J; Tkachuk VA; Zanga G; Carra A; Chertcoff A; Fernandez Liguori N; Lazaro L; Menichini ML; Miguez J; Orzuza G; Palavecino A; Pappolla A; Pigretti S; Pita C; Ruiz E; Silva B; Zentil G
Mult Scler Relat Disord; 2022 Jan; 57():103329. PubMed ID: 35158443
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder.
Lin W; Chou CH; Yang FC; Tsai CK; Lin YK; Sung YF
Front Immunol; 2023; 14():1115120. PubMed ID: 37122715
[TBL] [Abstract][Full Text] [Related]
12. Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod.
Fragoso YD; Adoni T; Gomes S; Goncalves MVM; Parolin LF; Rosa G; Ruocco HH
Clin Drug Investig; 2019 Sep; 39(9):909-913. PubMed ID: 31152369
[TBL] [Abstract][Full Text] [Related]
13. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
Delgado S; Hernandez J; Tornes L; Rammohan K
BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.
Derfuss T; Bergvall NK; Sfikas N; Tomic DL
Curr Med Res Opin; 2015; 31(9):1687-91. PubMed ID: 26121423
[TBL] [Abstract][Full Text] [Related]
15. Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.
Sato K; Niino M; Kawashima A; Yamada M; Miyazaki Y; Fukazawa T
Intern Med; 2018 Sep; 57(18):2647-2655. PubMed ID: 29709955
[TBL] [Abstract][Full Text] [Related]
16. Transitioning From S1P Receptor Modulators to B Cell-Depleting Therapies in Multiple Sclerosis: Clinical, Radiographic, and Laboratory Data.
Rowles WM; Hsu WY; McPolin K; Li A; Merrill S; Guo CY; Green AJ; Gelfand JM; Bove RM
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35581005
[TBL] [Abstract][Full Text] [Related]
17. Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients.
Bianco A; Lucchini M; Totaro R; Fantozzi R; De Luca G; Di Lemme S; Presicce G; Evangelista L; Di Tommaso V; Pastorino R; De Fino C; De Arcangelis V; Centonze D; Mirabella M
Neurotherapeutics; 2021 Oct; 18(4):2598-2607. PubMed ID: 34494237
[TBL] [Abstract][Full Text] [Related]
18. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
Havla JB; Pellkofer HL; Meinl I; Gerdes LA; Hohlfeld R; Kümpfel T
Arch Neurol; 2012 Feb; 69(2):262-4. PubMed ID: 22332194
[TBL] [Abstract][Full Text] [Related]
19. Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.
Członkowska A; Smoliński Ł; Litwin T
Neurol Neurochir Pol; 2017; 51(2):156-162. PubMed ID: 28209440
[TBL] [Abstract][Full Text] [Related]
20. Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study.
Callens A; Leblanc S; Le Page E; Edan G; Jourdain A; Coustans M; Wiertlewski S; Laplaud D; Videt D; Lallement F; Leray E; Michel L
Mult Scler Relat Disord; 2022 Oct; 66():104066. PubMed ID: 35908450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
